Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | GPR119 | Q8TDV5 | 17/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024788 | 0.86 | CYP3A4 (0.69) | CYP3A4GPR119 | |
| SCHEMBL1128644 | 0.85 | CYP3A4 (1.00) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL12596517 | 0.83 | GPR119 (0.66) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL2016413 | 0.82 | CYP3A4 (0.73) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL12596356 | 0.81 | GPR119 (0.54) | CYP3A4GPR119 | |
| SCHEMBL2025637 | 0.81 | CYP3A4 (0.67) | CYP3A4GPR119 | |
| SCHEMBL2020920 | 0.80 | CYP3A4 (0.75) | CYP3A4GPR119 | |
| SCHEMBL515111 | 0.78 | GPR119 (0.57) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL16254799 | 0.78 | GPR119 (0.59) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL30588316 | 0.78 | GPR119 (0.57) | CYP3A4GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | GPR119, GCGR, GPR35 | CYP3A4 1059/4885GPR119 1/4885CYP2C9 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.